🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Global Health Concern

The sexually transmitted infection are on the rise globally, with figures suggesting over 82 million instances per year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the reality of growing infection rates, escalating drug resistance and the highly restricted treatment choices at this time.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance found that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in concurrent days. This medication, which is also used to treat urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to see it through.

“This approval represents a huge turning point in the therapy of superbug gonorrhoea, which previously has been evolving faster than antibiotic development.”

Research Study Results and Global Access

According to data released by a major medical journal, the new drug cured over nine in ten of cases of the STI. This places it at an equal footing with the current standard treatment, which uses a dual-drug approach. The research involved over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to register and commercialise the drug in numerous regions with limited resources.

Doctors on the front lines have expressed positive views. Access to a single-dose, oral treatment such as this is described as a "critical tool" for public health efforts. This is viewed as vital to alleviate the strain of the disease for patients and to prevent the spread of untreatable gonorrhoea globally.